Investment Thesis
Arcturus Therapeutics is a development-stage biotech facing severe operational challenges with revenue collapsing 46% YoY to just $2.1M, while burning $28.9M in operating losses. The company maintains adequate liquidity with $211.4M cash reserves, but lacks a demonstrated path to profitability or revenue recovery, making it fundamentally distressed despite balance sheet strength.
Strengths
- Strong cash position of $211.4M provides 10+ year operating runway at current burn rate
- Minimal leverage with debt-to-equity of 0.08x and only $15.0M long-term debt
- Excellent liquidity with current ratio of 6.31x, reducing near-term bankruptcy risk
Risks
- Revenue collapse of 46% YoY to critically low $2.1M indicates severe business deterioration
- Massive operating losses of $28.9M with negative operating margin of -1403.7% showing unsustainable unit economics
- Negative operating and free cash flow of -$19.4M annually means cash reserves are only buffer, not sustainable model
- No visible path to profitability or revenue growth despite existing product/asset portfolio
Key Metrics to Watch
- Revenue growth rate and ability to stabilize/reverse 46% decline
- Operating cash flow trajectory and timeline to positive cash generation
- Cash burn rate relative to remaining reserves and runway
- FDA approvals or clinical trial results that could restore revenue streams
Financial Metrics
Revenue
2.1M
Net Income
-27.0M
EPS (Diluted)
$-0.95
Free Cash Flow
-19.4M
Total Assets
245.4M
Cash
211.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-1,403.7%
Net Margin
-1,308.3%
ROE
-14.1%
ROA
-11.0%
FCF Margin
-943.3%
Balance Sheet & Liquidity
Current Ratio
6.31x
Quick Ratio
6.31x
Debt/Equity
0.08x
Debt/Assets
22.0%
Interest Coverage
N/A
Long-term Debt
15.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T09:30:08.100704 |
Data as of: 2026-03-31 |
Powered by Claude AI